Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Pieris Pharmaceuticals News

    11,336 $ -4,39% -0,52 $
    In : 10,590 € | 22.04.24 15:44:26 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A12G4Q
    ISIN: US7207951036
    US-Symbol: PIRS
    Typ: Aktie

    Warnung
    Dieses Wertpapier ist nicht mehr aktuell.

    Pieris Pharmaceuticals News

    27.09.23 - PR Newswire
    Thinking about buying stock in Soleno Therapeutics, Lovesac, Pieris Pharmaceuticals, Lithium Americas, or Fisker?
    Thinking about buying stock in Soleno Therapeutics, Lovesac, Pieris Pharmaceuticals, Lithium Americas, or Fisker? PR Newswire
    08.09.22 - ACCESSWIRE
    Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
    BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
    24.08.22 - ACCESSWIRE
    Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
    BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    04.08.22 - ACCESSWIRE
    Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
    COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT
    28.07.22 - ACCESSWIRE
    Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
    BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    02.06.22 - ACCESSWIRE
    Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
    BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    18.05.22 - ACCESSWIRE
    Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
    BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    11.05.22 - ACCESSWIRE
    Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
    Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT
    04.05.22 - ACCESSWIRE
    Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
    BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    23.04.22 - The Motley Fool
    3 riskante Aktien mit großem Potenzial
    Viele Menschen wollen nur „sichere“, „ausgereifte“ oder „langweilige“ Aktien besitzen und ignorieren die Chancen auf der riskanten Seite des Aktienuniversums. Auf diese Weise ...
    01.03.22 - ACCESSWIRE
    Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
    COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST
    23.02.22 - ACCESSWIRE
    Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
    BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
    14.01.22 - ACCESSWIRE
    Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
    BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    03.01.22 - ACCESSWIRE
    Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
    BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    11.11.21 - ACCESSWIRE
    Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
    BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
    08.11.21 - ACCESSWIRE
    Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
    BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel ...
    02.11.21 - ACCESSWIRE
    Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
    Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT
    26.10.21 - ACCESSWIRE
    Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
    BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
    06.10.21 - ACCESSWIRE
    Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer
    BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
    09.09.21 - ACCESSWIRE
    Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
    BOSTON, MA / ACCESSWIRE / September 9, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...

    Newssuche

    Videos

    23.04.24
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: UH45D5 Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »